Association of Adjuvant Radiotherapy of Non-metastatic Breast Carcinoma With Immunomodulation and Circulating Tumor Cell Phenotype in Relation to Patient Age.
Launched by UNIVERSITY OF JENA · May 25, 2021
Trial Information
Current as of July 04, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how additional radiation therapy after surgery affects certain cancer cells in the blood of women with early-stage breast cancer. The researchers want to see if the characteristics of these cells and the body's immune response change based on the patient's age. To do this, they will collect blood samples from participants at various times after their tumor is removed and during their radiation treatment. They are particularly interested in understanding how these factors might help identify important markers that could predict how well a patient might respond to treatment.
Women aged 65 to 74 with confirmed early-stage invasive breast cancer who are planning to undergo surgery followed by radiation therapy may be eligible to participate. To join, women must not have certain conditions like inflammatory breast cancer or previous exposure to radiation therapy. Participants can expect to provide blood samples and have their tumor tissues analyzed to help researchers learn more about the relationship between radiation, cancer cells, and the immune system. This study is currently looking for participants, and the findings could lead to better treatment options in the future.
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Primary diagnosis histologically confirmed invasive breast carcinoma pT1-4 pN0 or pN+ cM0
- • curative-intended breast-conserving therapy (BET) ± (neo-) adj. system therapy with subsequent adjuvant radiotherapy of the breast ± lymphatic drainage system planned
- • informed consent of the patient
- Exclusion Criteria:
- • DCIS, Inflammatory breast carcinoma
- • Recurrence situation
- • Presence of distant metastases
- • Second malignancies \< 10 years prior to diagnosis of breast carcinoma
- • Prior exposure to radiotherapy
About University Of Jena
The University of Jena, a prominent research institution located in Germany, is dedicated to advancing medical science through innovative clinical trials. With a strong emphasis on interdisciplinary collaboration and cutting-edge research, the university engages in a wide range of studies aimed at improving patient outcomes and enhancing healthcare practices. Its commitment to ethical standards and rigorous scientific methodology ensures that trials conducted under its auspices contribute valuable insights to the medical community. Through partnerships with various healthcare providers and industry stakeholders, the University of Jena strives to translate research findings into practical applications that benefit society at large.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Jena, , Germany
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials